Document Detail

Recovery after severe refractory status epilepticus and 4 months of coma.
MedLine Citation:
PMID:  21956717     Owner:  NLM     Status:  Publisher    
New-onset refractory status epilepticus (NORSE) describes a prolonged seizure state of unknown etiology that occurs in a person without prior seizures.(1) The prognosis in the literature is poor.(1-4) We present a patient with NORSE who recovered after 4 months of coma.
Rebecca Bausell; Alexandra Svoronos; Laura Lennihan; Lawrence J Hirsch
Related Documents :
8839717 - Ok-432 therapy of lymphangiomas in children.
17296397 - Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinu...
24379947 - The comparative morphometric study of the posterior cranial fossa : what is effective a...
17374317 - Treatment of focal hyperhidrosis.
24765827 - To study the role of antibiotic+steroid irrigation of the middle ear in active chronic ...
16446517 - Glycoprotein iib/iiia inhibitors during rescue percutaneous coronary intervention in ac...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-9-28
Journal Detail:
Title:  Neurology     Volume:  -     ISSN:  1526-632X     ISO Abbreviation:  -     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-9-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
From the Comprehensive Epilepsy Center, Columbia University Medical Center, New York, NY. Dr. Hirsch is currently affiliated with Yale University School of Medicine, Division of Epilepsy and EEG, Yale Comprehensive Epilepsy Center, New Haven, CT.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Different clinical and neuropathologic phenotypes of familial ALS with A315E TARDBP mutation.
Next Document:  Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.